GO
Loading...

AstraZeneca PLC

More

  • AstraZeneca is stopping a clinical trial of its blockbuster cholesterol fighter Crestor early because of the clear benefits of the medicine compared to placebo, the company said on Monday.

  • One Giant Leap for MannKind Monday, 10 Mar 2008 | 5:11 PM ET

    Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.

  • AstraZeneca Earnings Fall, Cost Cuts to Help '08 Thursday, 31 Jan 2008 | 12:40 PM ET

    AstraZeneca gave a cautious outlook for the year ahead on Thursday after meeting analyst forecasts with a 3 percent fall in 2007 earnings, and said market conditions remained challenging.

  • Merck And Schering Reeling From Vytorin Study Thursday, 24 Jan 2008 | 1:56 PM ET

    ImpactRx--which follows prescription writing for the industry, investors and analysts--is out with a press release this afternoon assessing the damage to Merck and Schering-Plough's cholesterol franchise of Vytorin and Zetia.

  • Novartis Boosts Shareholder Return as Profit Sinks Thursday, 17 Jan 2008 | 12:11 PM ET

    Swiss drug maker Novartis said Thursday its fourth-quarter profit fell sharply, mainly due to restructuring costs, but that it would increase returns to shareholders with a new buyback program and an increase to its dividend.

  • Merck, Schering in Vytorin Victory Wednesday, 16 Jan 2008 | 12:40 PM ET

    The American College of Cardiology is weighing in on the controversial ENHANCE study that has battered shares of Merck and Schering-Plough over the past couple of days. Most notably I think is that the ACC says, "There should be no reason for patients to panic."

  • EU Raids Drug Companies in Broad Inquiry Wednesday, 16 Jan 2008 | 10:20 AM ET

    The European Commission raided some of the world's largest drugmakers on Wednesday, launching a broad investigation into whether they made illegal deals or abused patents to limit competition and harm consumers.

  • The 'Supply Chain': Stocks That Beat the S&P Thursday, 10 Jan 2008 | 4:42 PM ET

    Kevin O'Marah, chief strategist at AMR Research, has developed a unique "supply-chain strategy" -- and uses it to compile a Top 25 stocks list that beat the 2007 market hands-down.

  • Pete's Anatomy Friday, 4 Jan 2008 | 6:58 PM ET

    You’ve probably noticed one of the many scenic TV commercials that advertise prescription drugs. But did you notice what some of them are attempting to sell you?

  • Did Genentech Back Down or Backpedal? Friday, 21 Dec 2007 | 12:11 PM ET

    So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.

  • Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.

  • Eli Lilly

    Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.

  • Novartis Cuts, While Biogen Idec Cuts And Runs Thursday, 13 Dec 2007 | 4:06 PM ET
    Novartis

    Novartis is the latest company to brand its downsizing, cost-cutting campaign. The Swiss drugmaker is calling its initiative, "Forward". It's not an acronym. So, "Forward" means Novartis is going to try to save $1.6 billion in 2010 and get rid of 2,500 employees. Although I don't think "Forward" is the word which begins with "f" that the affected workers would use to describe the initiative.

  • Biogen Idec Gets No Takeover Bids; Stock Plummets Wednesday, 12 Dec 2007 | 5:05 PM ET
    Carl Icahn

    Biogen Idec said after markets closed Wednesday that it ended its review of strategic options after failing to receive any definitive takeover bids.

  • AstraZeneca Gets New US Approval for Seroquel XR Friday, 16 Nov 2007 | 8:58 AM ET

    AstraZeneca said on Friday that U.S. health regulators had approved Seroquel XR, an extended-release version of one of its top-selling drugs, as a maintenance treatment for adult schizophrenia patients.

  • Wider Use of Big-Selling Drug Crestor Approved Friday, 9 Nov 2007 | 5:28 AM ET

    AstraZeneca has won U.S. approval to market its cholesterol-lowering drug Crestor to treat the clogging of arteries, which may boost sales of the blockbuster drug in an increasingly competitive market.

  • Zocor

    This morning we got more evidence about the havoc generic Zocor is wreaking on all of the companies that make brand-name statins--the pills to fight cholesterol. AstraZeneca is the latest casualty. On a down day in the markets AZN is one of the biggest losers in the sector.

  • Crestor Competition Overshadows AstraZeneca Results Thursday, 1 Nov 2007 | 8:11 AM ET

    AstraZeneca profits fell 14 percent in the third quarter, hit by competition from cheap generics plus acquisition and restructuring charges, the Anglo-Swedish drugmaker said on Thursday.

  • Lipitor

    Pfizer has been using Dr. Robert Jarvik, the inventor of the Jarvik Artificial Heart, for quite some time now as its Lipitor "celebrity" pitchman. But recently I've noticed something remarkable creeping into his copy--the script he reads for TV and radio spots and the text that appears in the print ads.

  • Biogen Idec Earnings A 'Huge Swing and a Miss' Tuesday, 23 Oct 2007 | 12:13 PM ET

    Biotech giant Biogen Idec posted some disappointing third-quarter results, falling short of Wall Street expectations across the board. Does it matter, since the company has announced it's up for sale? Biotech analyst Christopher Raymond of Robert W. Baird thinks it does.